Ana Colette Maurício

University of Porto

Ana Colette Maurício has a degree in Veterinary Medicine, a Ph.D. in Veterinary Sciences from the Faculty of Veterinary Medicine (FMV) – University of Lisbon (UTL). Presently she is the Associate Professor with Habilitation in Veterinary Sciences at Abel Salazar Institute of Biomedical Sciences from University of Porto (ICBAS-UP), Head of the Veterinary Clinics Department, Director of the Veterinary Sciences Doctoral Program, Vice-President of the Pedagogic Council at ICBAS-UP, and Member of the Ethics Commission for Health Sciences from University of Porto. She is the Scientific Coordinator of the Regenerative Medicine and Experimental Surgery research sub-unit from Animal Science Studies Centre (CECA), Institute of Sciences, Technologies and Agro Environment from University of Porto (ICETA). She is one of the founding shareholders of Biosckin, Molecular and Cell Therapies, S.A, a private bank of umbilical cord blood and umbilical cord matrix stem cells authorized by the national authorities, also working in the development of new cell therapies and medical devices. She created a multidisciplinary team that has a crucial role in the development of biomaterials and cellular therapies, allowing a close share of knowledge between biomaterials design, development of cellular systems, and clinicians’ needs. She is the supervisor of several post-graduate students, co-author of a large number of scientific articles and book chapters. She has been a principal researcher of several national and international scientific projects.

2books edited

8chapters authored

Latest work with IntechOpen by Ana Colette Maurício

Umbilical cord blood (UCB) and, more recently, umbilical cord tissue (UCT) have been stored cryopreserved in private and public cord blood and tissue banks worldwide, since the umbilical cord blood was used for the first time in a child with Fanconi anemia with his HLA-identical sibling, following strict guidelines that imply high-quality standards and total rastreability of these units. The hematopoietic stem cells (HSCs) are clinically used in hematopoietic treatments for blood disorders and hemato-oncological diseases. Also, the mesenchymal stem cells (MSCs) isolated from the UCT and UCB, nowadays, can be used as coadjuvants of hematopoietic transplants. In the near future, these stem cells will have a crucial role in regenerative medicine. For this reason, these cells have been tested in several clinical trials and compassive treatments in children and adults, concerning a wide range of pathologies and diseases, for instance, for the treatment of cerebral paralysis. Considering the worldwide availability of UCB and UCT units and the absence of ethical concerns will probably become the best sources for cell-based therapies for hematological and nonhematological pathologies. The UCB will also have a crucial role in neonatology-predictive analysis in the near future.

Go to the book